Ordering Recommendation

Germline analysis of the BRCA1 and BRCA2 genes in individuals with a suspected diagnosis of hereditary breast and ovarian cancer (HBOC) syndrome. When a relative has a previously identified pathogenic sequence variant, see Familial Mutation, Targeted Sequencing (2001961).

Mnemonic

BRCA NGS

Methodology

Massively Parallel Sequencing/Multiplex Ligation-dependent Probe Amplification

Performed

Varies

Reported

15-17 days

New York DOH Approval Status

Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Specimen Required

Patient Preparation
Collect

Lavender (EDTA) or Yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 2 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Serum or plasma; grossly hemolyzed or frozen specimens

Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Note

Genes tested: BRCA1 (NM_007294), BRCA2 (NM_000059)

Hotline History

N/A

CPT Codes

81162

Components

Component Test Code* Component Chart Name LOINC
3001861 BRCA Specimen 31208-2
3001862 BRCA Interp 94191-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Hereditary Breast
  • Ovarian Cancer
BRCA1 and BRCA2-Associated HBOC Syndrome Panel, Sequencing and Deletion/Duplication